Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

8.78
+0.33503.97%
Volume:2.40M
Turnover:20.59M
Market Cap:1.83B
PE:-20.41
High:8.81
Open:8.34
Low:8.28
Close:8.44
Loading ...

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
Yesterday

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire
·
Yesterday

BioCryst Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
29 Apr

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
28 Apr

BioCryst to Report First Quarter 2025 Financial Results on May 5

GlobeNewswire
·
21 Apr

Bank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)

TIPRANKS
·
17 Apr

BioCryst Pharmaceuticals Price Target Maintained With a $11.00/Share by RBC Capital

Dow Jones
·
11 Apr

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

Zacks
·
11 Apr

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis

MT Newswires Live
·
11 Apr

BRIEF-Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting Officer - SEC Filing

Reuters
·
11 Apr

BioCryst CEO to serve as interim CFO

TIPRANKS
·
11 Apr

BioCryst Pharmaceuticals - on April 7, Jon P. Stonehouse Appointed Interim CFO & Interim Principal Accounting Officer - SEC Filing

THOMSON REUTERS
·
11 Apr

BioCryst Pharmaceuticals Price Target Maintained With a $15.00/Share by Needham

Dow Jones
·
10 Apr

RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)

TIPRANKS
·
05 Apr

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
04 Apr

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Apr

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire
·
03 Apr

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.
·
28 Mar

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

Simply Wall St.
·
19 Mar

The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295%

Simply Wall St.
·
18 Mar